Sleeping Beauty Gene Therapy from Liver to BOECs

从肝脏到 BOEC 的睡美人基因治疗

• 批准号: 7111137
• 负责人: CLIFFORD John STEER
• 金额: $ 36.5万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7111137
• 关键词: biotechnology; blood cells; cell line; coagulation factor IX; coagulation factor VII; disease /disorder model; gene delivery system; gene expression; gene therapy; genetic manipulation; genetically modified animals; hemophilia B; human genetic material tag; laboratory mouse; liver cells; metabolomics; nonhuman therapy evaluation; protein engineering; recombinant proteins; thromboplastin; tissue /cell culture; transfection; transfection /expression vector; transposon /insertion element

DESCRIPTION (provided by applicant): Gene therapy using viral vectors has had limited success in the treatment of the various types of hemophilia. Both the host response and the unique characteristics of the vector systems have made it difficult to achieve persistent long-term transgene expression. An additional complication in the treatment of hemophilia by replacement therapy is the development of inhibitory antibodies to the clotting factor. In fact, this has prompted the use of rFVIIa in an effort to induce hemostasis via tissue factor (TF) independent FX activation at the platelet surface. The main objective of this research project is to evaluate the nonviral Sleeping Beauty transposon (SB-Tn) vector for gene therapy in a mouse model of factor IX deficiency. This objective tests our hypothesis that separate or combined expression of FIX, rFVIIa and soluble TF (sTF) transgenes will improve the disease phenotype. The first specific aim is designed to optimize in cell culture (i) the Tn design for maximal transposition and persistent gene expression of the coagulation factors IX, an engineered rFVIIa and sTF; and (ii) the nonviral delivery systems to hepatocytes via the asialoglycoprotein receptor by several different ligand moieties. The second specific aim evaluates the capacity of the best Tn vectors/delivery systems to promote Tn insertion and persistent transgene expression in vivo. The therapeutic effects in vivo for expression of FIX, rFVIIa, and/or sTF will be monitored and quantitated by the relevant metabolic parameters. The dosing regimen, the delivery vehicle and route of administration will be optimized for efficiency of transposition and safety. The third specific aim is designed to evaluate the potential use of blood outgrowth endothelial cells (BOECs) as a vehicle of transgene expression via SB transposition. The transposition and expression characteristics of the different SB-Tns expressing FIX, TF and/or rFVIIa will be examined in BOECs both individually and in pair wise combinations. The ex vivo engineered BOECs will be infused back into hemophilia B mice, and analyzed for long-term expression and effect on the bleeding diathesis of the FIX deficient animals. The major goals of this research proposal are to (i) optimize Tn designs and nonviral delivery systems that provide therapeutic levels of FIX, rFVIIa and/or sTF with SB-mediated gene transfer; (ii) identify the best in vivo conditions for correction of the clotting disorder in animal models of | hemophilia B; and (iii) characterize the BOECs potential as an autologous vehicle for persistent transgene expression.

描述（由申请人提供）：使用病毒载体的基因治疗在治疗各种类型血友病方面取得了有限的成功。宿主的反应和载体系统的独特特性使其难以实现持久、长期的转基因表达。通过替代疗法治疗血友病的另一个并发症是对凝血因子的抑制性抗体的发展。事实上，这促使使用rFVIIa，通过在血小板表面激活组织因子（TF）无关的FX来诱导止血。本研究项目的主要目的是评估非病毒性睡美人转座子（SB-Tn）载体在因子IX缺乏症小鼠模型中的基因治疗作用。这一目的验证了我们的假设，即单独或联合表达FIX、rFVIIa和可溶性TF （sTF）转基因将改善疾病表型。第一个特定目标是优化细胞培养(i) Tn设计，以最大限度地转移和持续表达凝血因子IX，一个工程化的rFVIIa和sTF；（ii）通过几种不同的配体片段通过asialal糖蛋白受体传递到肝细胞的非病毒传递系统。第二个具体目标是评估最佳Tn载体/传递系统促进Tn插入和体内持续转基因表达的能力。体内对FIX、rFVIIa和/或sTF表达的治疗效果将通过相关代谢参数进行监测和定量。将优化给药方案、给药载体和给药途径，以提高转运效率和安全性。第三个具体目标是评估血液外生内皮细胞（BOECs）作为通过SB转位转基因表达载体的潜在用途。我们将在boec中单独和成对组合研究表达FIX、TF和/或rFVIIa的不同SB-Tns的转位和表达特征。将体外工程boec输注回B型血友病小鼠，分析其长期表达情况及对FIX缺陷小鼠出血素质的影响。本研究计划的主要目标是：(i)优化Tn设计和非病毒递送系统，通过sb介导的基因转移提供治疗水平的FIX、rFVIIa和/或sTF；（ii）确定纠正|血友病B动物模型凝血障碍的最佳体内条件；（iii）表征boec作为持续转基因表达的自体载体的潜力。